Cargando…
Pembrolizumab-Induced Adrenal Insufficiency Presenting Eight Months After Cessation of Treatment
Pembrolizumab is a monoclonal antibody that functions as an immune checkpoint inhibitor. It is an FDA-approved immunotherapy used to treat various malignancies. With its wide use in cancer therapy, there are many known side effects. It is a common cause of endocrinopathies such as thyroid disease an...
Autores principales: | Zilberman, Stephanie, Rafii, Daniel C, Giunta, Judith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374333/ https://www.ncbi.nlm.nih.gov/pubmed/37519548 http://dx.doi.org/10.7759/cureus.41049 |
Ejemplares similares
-
Autoimmune Myasthenia, Primary Adrenal Insufficiency, and Progressive Hypothyroidism Due to Pembrolizumab and Axitinib Combination Regimen
por: Figueroa-Perez, Nikole, et al.
Publicado: (2021) -
Case Report of Disseminated Adrenal Histoplasmosis and Secondary Adrenal Insufficiency
por: Jagadish, Ishitha, et al.
Publicado: (2022) -
Vanishing Adrenal Glands: Bilateral Adrenal Hemorrhage With Adrenal Insufficiency in COVID-19 Infection
por: Majety, Priyanka, et al.
Publicado: (2023) -
Adrenal Insufficiency Secondary to Bilateral Adrenal Hemorrhage: A Case Report
por: Bashari, Waiel A, et al.
Publicado: (2020) -
A Case of Bilateral Adrenal Hemorrhage: The Exceptional Cause of Adrenal Insufficiency
por: Khakwani, Aemen S, et al.
Publicado: (2022)